Skip to content

Predictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis

Predictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05458635
Enrollment
60
Registered
2022-07-14
Start date
2019-08-01
Completion date
2021-03-15
Last updated
2022-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension, Hypersensitivity Pneumonitis

Brief summary

Hypersensitivity pneumonitis (HP) is a complex immune mediated disorders caused by repeated inhalation of and sensitization to wide range of antigens including organic particles and chemical compounds, leading to exaggerated immuneresponse. Hypersenstivity pneumonitis is a common form of diffuse parenchymal lung diseases in Egypt .Pulmonary hypertension has been found as a complication of a number of diseases affecting the lung interstitium, including hypersensitivity pneumonitis, with subsequent affection of the life expectancy Rationale of the study: to find predictors for the development of pulmonary hypertension in patients with hypersensitivity pneumonitis

Detailed description

Cross sectional study included 60 patients with established diagnosis of HP , work up includes history of exposure, clinical examination, HRCT chest, ABGs,6MWD, desaturation degree , spirometry, echocardiography and right heart catheter in patients with high echo probability of PH.

Interventions

Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
29 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* All patients with confirmed diagnosis of Hypersensitivity pneumonitis

Exclusion criteria

* Other interstitial lung diseases

Design outcomes

Primary

MeasureTime frameDescription
Percentage of pulmonary hypertension in patients with HP6 monthsprimary oucome

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026